VKTX
Viking Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.67
+6.06%Next report
Analyst consensus
- Next report date
- Feb 10, 2027
- EPS estimate
- -$1.38
- Revenue estimate
- —
Latest reported
- Last report date
- Oct 28, 2026
- EPS actual
- -$1.55
- EPS estimate
- -$1.06
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -31.6%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Strong Buy
- Price target
- $91
- PT range
- $65 – $118
- Analysts
- 4
4 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 28, 2026 | -$1.06 | -$1.55 | Miss -46.23% | — |
| Jul 29, 2026 | -$1.23 | -$1.10 | Beat 10.57% | — |
| Apr 29, 2026 | -$1.01 | -$1.37 | Miss -35.64% | — |
| Feb 11, 2026 | -$0.89 | -$1.38 | Miss -55.06% | — |
| Oct 22, 2025 | -$0.70 | -$0.81 | Miss -15.71% | — |
| Jul 23, 2025 | -$0.44 | -$0.58 | Miss -31.82% | — |
| Apr 23, 2025 | -$0.34 | -$0.41 | Miss -20.59% | — |
| Feb 5, 2025 | -$0.28 | -$0.32 | Miss -14.29% | — |
| Oct 23, 2024 | -$0.24 | -$0.22 | Beat 8.33% | — |
| Jul 24, 2024 | -$0.26 | -$0.20 | Beat 23.08% | — |
| Feb 7, 2024 | -$0.25 | -$0.25 | In line | $436.0K |
| Oct 25, 2023 | -$0.22 | -$0.23 | Miss -4.55% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 10, 2027